| Literature DB >> 35685549 |
Chen Fang1, Kun Zuo1, Wanjing Zhang1, Jiuchang Zhong1, Jing Li1, Li Xu1, Xinchun Yang1.
Abstract
Background: In our previous studies, we found a disordered taxonomic composition and function of gut microbiota (GM) in atrial fibrillation (AF) patients. However, direct evidence about the association between dysbiotic microbiota and thromboembolic risk in AF is lacking. Aims: In this study, we analyzed the interaction of GM and related functional patterns in AF with different CHA2DS2-VASc scores to assess its potential as a biomarker for predicting stroke risk. Patients and Methods. The CHA2DS2-VASc score was used for thromboembolic risk stratification in AF according to American Heart Association (AHA) guidelines. We investigated the taxonomic and functional annotation of GM based on metagenomic data from 50 AF patients (32 with high thromboembolic risk (CHA2DS2-VASc score ≥2 (males) or CHA2DS2-VASc score ≥3 (females)) and 18 individuals with low thromboembolic risk (CHA2DS2-VASc score <2 (males) or CHA2DS2-VASc score <3 (females))).Entities:
Mesh:
Year: 2022 PMID: 35685549 PMCID: PMC9159190 DOI: 10.1155/2022/7942605
Source DB: PubMed Journal: Int J Clin Pract ISSN: 1368-5031 Impact factor: 3.149
Clinical characteristics of all subjects.
| Low CHA2DS2-VASc score | High CHA2DS2-VASc score |
| |
|---|---|---|---|
| Number | 18 | 32 | |
| Score | 0.8 ± 0.8 | 3.7 ± 1.2 | |
| Congestive heart failure | 0 | 0 | |
| Male/female | 12/6 | 20/12 | 1.000 |
| Age, years | 54.0 ± 9.2 | 69.7 ± 7.1 | <0.001 |
| HTN (%) | 2 (11.1) | 25 (78.1) | <0.001 |
| DM (%) | 2 (11.1) | 10 (31.3) | 0.170 |
| Stroke/TIA prior (%) | 0 (0.0) | 4 (12.5) | 0.283 |
| Vascular disease (%) | 3 (16.7) | 29 (90.6) | <0.001 |
| pAF/psAF | 13/5 | 17/15 | 0.237 |
| Time of AF history, years | 0.7 (0.2, 2.5) | 1.5 (0.2, 5.8) | 0.460 |
| BMI, kg/m2 | 26.3 (24.0, 29.3) | 26.5 (23.6, 28.4) | 0.952 |
| LVEDD, mm | 47.3 ± 3.6 | 47.2 ± 3.7 | 0.938 |
| LVESD, mm | 28.5 (27.5, 31.3) | 29.0 (27.0, 33.0) | 0.654 |
| LVEF (%) | 67.7 ± 5.0 | 66.6 ± 6.3 | 0.548 |
| LAE (%) | 9 (50.0) | 21 (65.6) | 0.242 |
| TC, mmol/L | 4.6 ± 1.0 | 3.8 ± 1.0 | 0.009 |
| LDL-C, mmol/L | 2.6 ± 0.7 | 2.2 ± 0.9 | 0.073 |
| HDL-C, mmol/L | 1.1 ± 0.4 | 1.1 ± 0.3 | 0.950 |
| TG, mmol/L | 3.1 ± 5.4 | 1.4 ± 0.5 | 0.185 |
| AST, U/L | 22.0 ± 12.6 | 20.6 ± 5.8 | 0.600 |
| ALT, U/L | 26.9 ± 15.9 | 21.5 ± 10.5 | 0.201 |
| TBil, | 12.2 (10.1, 20.3) | 14.6 (10.0, 26.5) | 0.664 |
| sCr, | 69.7 ± 13.3 | 72.9 ± 19.5 | 0.531 |
| UA, | 341.3 ± 71.5 | 327.0 ± 68.6 | 0.489 |
| WBC, ×109/L | 5.7 ± 1.6 | 6.3 ± 1.4 | 0.206 |
| HGB, g/L | 141.9 ± 17.1 | 135.0 ± 13.5 | 0.122 |
| PLT, ×109/L | 218.2 ± 46.7 | 213.6 ± 48.7 | 0.748 |
| ALB, g/L | 41.2 ± 2.9 | 39.5 ± 2.9 | 0.055 |
| FBG, mmol/L | 4.9 (4.4, 5.6) | 5.2 (4.6, 6.0) | 0.322 |
| HbA1c (%) | 6.0 ± 0.9 | 6.3 ± 0.7 | 0.348 |
Data are expressed as mean ± SD, median (first quartile, third quartile). AF, atrial fibrillation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; BMI, body mass index; DM, diabetes mellitus; FBG, fasting blood glucose; HTN, hypertension; HGB, hemoglobin; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LVEDD, left ventricular and diastolic diameter; LVESD, left ventricular and systolic systolic diameter; LVEF, left ventricular ejection fraction; LAE, left atrial enlargement, pAF, paroxysmal atrial fibrillation; psAF, persistent atrial fibrillation; PLT, platelet; sCr, serum creatinine; TC, total cholesterol; TG, triglyceride; TIA, transient ischemic attack; LDL-C, low-density lipoprotein cholesterol; TBil, total bilirubin; UA, uric acid, WBC white blood cell.
Figure 1GM in the high or low CHA2DS2-VASc score group. (a, b) Comparison of the microbial α diversity comprising Shannon index and Pielou evenness according to the genera profiles in two groups. The boxes represent the interquartile ranges, and the line inside represents the median. (c) A discrepancy in GM composition accessed by PLS-DA. (d) All samples classified into three enterotypes showing significantly different genera (Bacteroidetes, Prevotella, and Faecalibacterium) in the three enterotypes. P=2.23e − 07, P=3.91e − 04, and P=2.25e − 05, respectively. (e) The distribution of enterotypes was different between the two groups. Low vs. high; 38.89% vs. 37.50% for the enterotype characterized by Faecalibacterium; 33.33% vs. 25.00% for the enterotype characterized by Prevotella; 27.78% vs. 37.50% for the enterotype characterized by Bacteroides; P=0.736, χ2 test.
Figure 2Alterations of GM and related function in the high or low CHA2DS2-VASc score group. (a) LEfSe analysis revealed significant GM differences between the low (green) and high (red) CHA2DS2-VASc score groups at the threshold of absolute LDA score (log 10) >2.0. (b) Radar map presented the relative abundance and multiple in two groups of the top 10 species differentially enriched in AF patients with high CHA2DS2-VASc scores. Wilcoxon rank-sum test, adjust P < 0.05. (c, d) Annotation of GM function according to KEGG database between two groups. (c) PLS-DA showing a difference in the two groups. (d) The heat map revealed the shift in the relative abundance (log 10) of KOs across the two groups, and the potential functions of the KOs were presented on the right.
Figure 3Prediction score of thromboembolic risk in AF patients. (a, b) The most predictive tax of GM and KOs were presented, including 20 species and 22 KOs. (a) The heatmap shows the relative abundance (log 10) of 20 species (all P < 0.05). (b) The fold change (log 2) in the relative abundance of 22 KOs. (c) Correlations between 20 species and 22 KOs. Pearson's correlation coefficients were calculated. Red, positive correlation; blue, negative correlation. (d) ROC curve showed the relevant predictive value of the KO score, AUC = 0.993, 95% CI: 0.916–1.000, P < 0.001. (e) Mediation analysis on microbial diversity (Shannon index and Pielou's evenness), KO scores, LAVI, and thromboembolic risk of AF patients. VAF = 11.1%, P < 0.05. P < 0.05; P < 0.01; P < 0.001.